Fig. 1: Hsp90 inhibitors sensitize cells to CDC.

a, b K562 cells were incubated with geldanamycin (GA, 100 μM) (a) or radicicol (Rad, 100 μM) or with DMSO (0.5%) as control for 60 min at 37 °C. Then, the cells were washed and treated with antibody and NHS for 60 min at 37 °C. Percent lysis was determined by propidium iodide inclusion. c Ramos cells were incubated with geldanamycin (GA, 100 μM) or with DMSO (0.5%) as control for 60 min at 37 °C. Then, the cells were washed and treated with rituximab (3 μg/ml) and NHS (50%) for 60 min at 37 °C. Percent lysis was determined by propidium iodide inclusion. d K562 cells were treated with geldanamycin or with DMSO for 60 min, followed by antibody (30 min) and NHS (10 min, peak C5b-9 formation). The cells were then treated or not with trypsin and labeled with aE11 monoclonal antibody followed by a secondary FITC-labeled antibody. Mean fluorescence intensity (MFI) of bound C5b-9, representative of three independent experiments, is presented. *P < 0.05, **P < 0.01